Mert Kaşkal

Mert Kaşkal

Auto-generated profile, based on publicly available information

Mert Kaşkal

Liverpool Centre for Cardiovascular Sciences at Liverpool, Heart & Chest Hospital, Liverpool John Moores University and University of Liverpool, United Kingdom; Marmara University, School of Medicine, Department of Medical Pharmacology, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
SÇSelcan Tülü Çolak
Selcan Tülü Çolak
CVCaner Vizdiklar
Caner Vizdiklar
MKMert Kaşkal
Mert Kaşkal
VAVolkan Aydin
Volkan Aydin
OAOmer Atac
Omer Atac
AAAhmet Akici
Ahmet Akici
Background/aim: Elderly and very elderly individuals might be subject to different approaches for the treatment of hypertension. We aimed to compare drug utilization in hypertensive old patients and very old patients in primary care, along with the evaluation of potentially inappropriate drug prescribing. Materials and methods: In this cross-sectional study, we compared prescriptions of 65-79-year-old (old patient prescriptions [OPP], n = 433,988) vs. ≥80-year-old (very old patient prescriptions [VOPP], n = 134,079) with "essential hypertension" diagnosis, issued by 3:1 systematically-sampled primary care physicians (n = 1431) in İstanbul throughout 2016. Drug utilization patterns and distribution of antihypertensives based on drug class and combination status were evaluated. Frequency of potentially inappropriate drugs per Beers Criteria were identified and compared. Results: Antihypertensive monotherapy practice was less common in OPP than VOPP (43.3% vs. 45.3%; p < 0.001). In both groups, the most commonly prescribed drugs were beta-blockers for monotherapy (37.4% vs. 33.1%, p < 0.001) and thiazide diuretics for combined therapy (69.8% vs. 67.4%, p < 0.001). Metoprolol was the most commonly prescribed antihypertensive both in OPP and VOPP (15.3% vs. 14.8%). Furosemide was ranked 10th in OPP and 3rd in VOPP (2.7% vs. 5.5%). Cardiovascular system drugs were the most commonly encountered potentially inappropriate medications in both groups (263.9 vs. 283.4 per 10,000 prescriptions, p = 0.004). Regarding antihypertensive drugs, 2.2% of those in OPP and 2.4% of those in VOPP were identified as potentially inappropriate (p = 0.002). Conclusion: Prescribing preferences to old and very old patients mostly showed slight differences. Almost half of prescriptions comprising antihypertensive monotherapy might imply hesitancy to prescribe combinations. Overuse of risky drugs such as furosemide in both groups, especially in the very elderly, requires more attention.

18 December 2025 in European Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
MKMert Kaşkal
Mert Kaşkal
TBTommaso Bucci
Tommaso Bucci
MAMuath Alobaida
Muath Alobaida
SLSteven Ho Man Lam
Steven Ho Man Lam
MRMichele Rossi
Michele Rossi
Rebecca BurtonRebecca Burton
Rebecca Burton
Background: Chronic pericarditis is associated with significant cardiovascular morbidity, including atrial fibrillation (AF), heart failure (HF), and stroke. Colchicine is widely used in pericarditis management for its anti-inflammatory effects, but its impact on arrhythmias and other cardiovascular outcomes remains uncertain. Methods: We conducted a retrospective observational cohort study using the TriNetX global federated research network to assess the association between colchicine use and cardiovascular outcomes in in-patients with chronic pericarditis. Patients diagnosed with chronic adhesive and constrictive pericarditis with or without colchicine use between 2010 and 2024 were included. Propensity score matching (PSM) (1:1) was used to balance baseline characteristics. The primary outcome was 1-year incidence of AF. Secondary outcomes included all-cause mortality, ischemic stroke, acute myocardial infarction (AMI), acute HF, cardiac arrest, ventricular arrhythmias, and a composite cardiovascular outcome. Results: Of 8,120 patients hospitalized with chronic pericarditis, 1,064 received colchicine. 1,061 patients were matched in each group after PSM. The 1-year incidence of AF was similar between colchicine users and non-users (HR: 0.90, 95% CI: 0.76–1.06) after PSM. Colchicine use was associated with significantly lower risk of all-cause mortality (HR: 0.67, 95% CI: 0.54–0.84) and ischemic stroke (HR: 0.45, 95% CI: 0.29–0.67) after PSM. No significant differences were observed for AMI, cardiac arrest, HF, or ventricular arrhythmias. Conclusion: In this real-world cohort of patients with chronic pericarditis, colchicine did not increase the risk of AF. Colchicine was linked to significantly lower risks of all-cause mortality and ischemic stroke in hospitalized chronic pericarditis patients, suggesting potential systemic cardiovascular benefits.

5 November 2025 in JACC: Asia
Verified
Journal Article
Open access
MKMert Kaşkal
Mert Kaşkal
FFFreddy Frost
Freddy Frost

19 March 2026 in Respiratory Medicine
Verified
Journal Article
Closed access
MKMert Kaşkal
Mert Kaşkal
DWDennis Wat
Dennis Wat
DNDilip Nazareth
Dilip Nazareth
GLGregory Y.H. Lip
Gregory Y.H. Lip
FFFreddy Frost
Freddy Frost

17 October 2022 in Kocatepe Tıp Dergisi
Verified
Journal Article
Closed access
PDF file
ÖÇÖzlem Çevli̇k
Özlem Çevli̇k
MKMert Kaşkal
Mert Kaşkal
The interest on personalized medicine encourages researches on pharmacogenetics. The promotion of new analytical combinations in extensive drug development and also with the progression in the technologies for human gene cloning resulted in a great interest for pharmacogenetics. In last years the development on genetical sciences also influenced pharmacogenetics. Personalized medicine also includes areas such as stratified medicine and precision medicine and these terms are closely related with pharmacogenetics. Moderate response rates and the difference in drug effect on individuals focus pharmacogenetics on psychopharmacology area and antidepressants. It is considered that genetic factors may contribute %50 of antidepressant drug response. Additionally the genetical properties of the patient may effect the pharmacokinetics and pharmacodynamics of the antidepressants therefore the change in the effect and an increase in the side effects may be seen. The genes which codes serotonin transporter, 5-HTTLPR and SLC6A4 are commonly investigated and they are thought to be the main reasons of the difference in antidepressant drug responses. Also the difference in the activities of CYP 2D6 and CYP 2C19 may change the pharmacokinetics of the antidepressants and therefore the stable concentration of antidepressant leves in the plasma. These variations in the factors contributing to the drug levels may lead to a difference in the response rates of antidepressants. In this review, we focused on the pharmacogenetics of different classes of antidepressant drugs such as selective serotonine reuptake inhibitors, serotonin-noradrenaline reuptake inhibitors, tricyclic antidepressants and mono-amine oxidase inhibitors. We have compiled pharmacogenetic studies on antidepressants and effect of genetic variations on the drug responses.